LIPELLA PHARMACEUTICALS INC. Income Statement
LIPO|3 years of annual SEC 10-K data (FY2022-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$536,357
FY2024
Gross Profit
N/A
FY2024
Operating Income
-$5M
FY2024
Net Income
-$5M
FY2024
LIPELLA PHARMACEUTICALS INC. reported $536,357 in revenue and $5M in net loss for FY2024. Revenue has grown at a 70.7% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $536.4K | $449.6K | $184.2K |
| SG&A Expense | $2.0M | $2.2M | $226.2K |
| R&D Expense | $3.6M | $3.0M | $2.5M |
| Operating Income | -$5.1M | -$4.7M | -$2.6M |
| Interest Expense | - | $10.8K | $9.6K |
| Net Income | -$5.0M | -$4.6M | -$2.6M |
| EPS (Basic) | -$6.16 | -$0.64 | -$0.55 |
| EPS (Diluted) | -$6.16 | -$0.64 | -$0.55 |
| Shares Outstanding | 756.7K | 5.7M | 3.9M |
| Operating Margin | -947.2% | -1055.5% | -1406.3% |
| Profit Margin | -935.2% | -1027.3% | -1410.6% |